Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
For each program advanced by the Big Pharma, Vyriad will receive an upfront payment, milestone payments and royalties.
Darren Incorvaia
Nov 20, 2024 12:00pm
Novartis taps Ratio for $745M radiopharmaceutical pact
Nov 18, 2024 8:00am
Novartis pays Schrödinger $150M to form drug discovery pact
Nov 12, 2024 8:55am
VC firm, Chinese biotech launch autoimmune-focused Oblenio Bio
Nov 7, 2024 11:35am
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Oct 29, 2024 6:16am
Novartis inks $150M deal for autoimmune molecular glue
Oct 28, 2024 7:00am
